Patient demographics at baseline | ||
Teprotumumab group, N = 10 | Placebo, N = 12 | |
Age (years), mean (SD) | 50 (13) | 59 (7) |
Gender, (N) | ||
Male | 4 | 2 |
Female | 6 | 10 |
Race, (N) | ||
Caucasian | 10 | 10 |
Black | 0 | 0 |
Asian | 0 | 2 |
Smokers, (N) | 2 | 4 |
Months since diagnosis of Graves’ disease, mean (SD) | 16.4 (20) | 24.8 (41.3) |
Months since diagnosis of TED, mean (SD) | 5.8 (2.2) | 6.0 (2.3) |
TED, thyroid eye disease.